In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Access

Set Alert for Market Access

UK, Sweden Test Differing Antibiotic Market Models

Sweden and the UK are conducting differing ‘develop and test’ programs to assess so-called ‘pull’ incentives in which an antibiotics innovator will be paid an annual fee in return for an access guarantee for anti-infectives. The projects have drawn keen attention from other countries. 

Commercial Health Technology Assessment Market Access

Latest From Market Access

PBMI: Managing Specialty Drug Costs, Working With ICER And Promoting Transparency

Despite a reprieve last summer from the Trump administration’s proposed drug price rebate rule, speakers at the 25th annual Pharmacy Benefit Manager Institute kept the focus on price transparency and talked up new ways to manage drug costs for patients in need of treatment. 

BioPharmaceutical Commercial

Focusing On Collaborative Not ‘Innovative’ Ways To Pay

Innovation is defined by the Cambridge dictionary as “(the use of) a new idea or method.” The term is bandied about a great deal in the life sciences industry. Is it actually helpful to use the term so widely, or does the sector risk overlooking true innovation? This can be applied not only to the drugs coming to market, but how they are paid for as well.

Commercial Health Technology Assessment

Are Incentives Out Of Balance With Patient Need?

Incentives matter; they motivate us to do things. There is renewed interest in just what motivates the life sciences industry to make the choices it does when determining the diseases it will focus on, and how much effort it puts in. This stems from concern about too much effort going into some areas, and too little in others.

Market Access Research and Development Strategies

‘Regulatorism': A New Terminology For Medtech And Pharmaceutical Leadership Mindsets

The new regulatory professionalism drive sweeping over the global medtech and pharmaceutical sectors will lead to better value for all health care stakeholders. This is of particular relevance in regions such as Asia, where regulatory manpower is often at low levels. 

Asia Pacific Regulation

Mehta Analysis: Biopharma 3.0 – An Industry Society Could Cherish

As it enters a potentially golden decade, can biopharma seize the opportunity to overhaul its business model – and its reputation? Viren Mehta of Mehta Partners LLC discusses. 

Business Strategies Commercial

Meindert Boysen On What Companies Should Expect From NICE

In an exclusive interview, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.

Market Access Pricing Strategies
See All
UsernamePublicRestriction

Register